Cancer Antigens

License agreement focused on development of cancer vaccines

Published in Cancer Weekly, December 24th, 2002

Coley Pharmaceutical Group and GlaxoSmithKline (GSK) announced that the companies have entered into a license agreement for the development of prophylactic and therapeutic cancer vaccines combining Coley's CpG immunostimulatory oligonucleotides (oligos) and GlaxoSmithKline's cancer antigens.

The agreement, the second GSK-Coley license agreement, provides GSK with a worldwide nonexclusive license to Coley's proprietary CpG immunostimulatory oligos for use as adjuvants in cancer vaccines. In exchange, Coley has received $4 million in license issue fees and upon the achievement of certain milestones, will receive future payments, as well as license maintenance fees and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-12-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry